The pharmaceutical company Moberg Derma completed the second tranche of its share issue according to plan. During 2009, a total of SEK 40 million has been secured. The second tranche of SEK 10 million was directed primarily to existing shareholders. More than SEK 110 million has been raised since the company was established in March 2006.

"We are very pleased with the strong support from our investors. Through the new share issue financing has been secured for continued development of the product portfolio as well as initial commercialization activities," says Peter Wolpert, President and CEO of Moberg Derma.

Contact Moberg Derma
Peter Wolpert, President and CEO
Telephone: +46 8 - 522 307 00
Mobile: +46 70 - 735 71 35
E-mail: peter.wolpert@mobergderma.se

About Moberg Derma
Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights for the Nordic region. The company began operations at the Karolinska Institute in 2006 and currently has 10 employees. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se

This information was distributed by Cision